Expert Opinion on Pharmacotherapy最新文献_第9页

An update on pharmacotherapy for fungal infections in allogeneic stem cell transplant recipients. 异体干细胞移植受者真菌感染药物疗法的最新进展。

IF 2.5 3区医学

Expert Opinion on Pharmacotherapy Pub Date : 2024-08-01 Epub Date: 2024-08-13 DOI: 10.1080/14656566.2024.2387686

Paraskevi Panagopoulou, Emmanuel Roilides

{"title":"An update on pharmacotherapy for fungal infections in allogeneic stem cell transplant recipients.","authors":"Paraskevi Panagopoulou, Emmanuel Roilides","doi":"10.1080/14656566.2024.2387686","DOIUrl":"10.1080/14656566.2024.2387686","url":null,"abstract":"Introduction: Invasive fungal diseases (IFD) constitute a major cause of morbidity and mortality in hematopoietic stem cell transplantation (HSCT) recipients.Areas covered: We describe epidemiology, causes and risk factors of IFD in allogeneic HSCT discussing prophylaxis and treatment in various HSCT phases. We present the most recent studies on this thematic area, including novel data on currently available antifungals, i.e. formulations, dosing, safety, efficacy and therapeutic drug monitoring. Finally, we present the most recent relevant recommendations published. Literature search included PubMed, Scopus, and clinicaltrials.gov between January 2014 and April 2024.Expert opinion: The antifungal agents employed for prophylaxis and therapy should be predicated on local epidemiology of IFD. Fluconazole prophylaxis remains a first-line choice before engraftment when the main pathogen is Candida spp. After engraftment, prophylaxis should be with mold-active agents (i.e. triazoles). For candidiasis, echinocandins are suggested as first-line treatment, whereas aspergillosis responds well to mold-active azoles and liposomal amphotericin B (L-AmB). For mucormycosis, treatment of choice includes L-AmB and isavuconazole. Choice between fever-driven and diagnostics-driven strategies remains equivocal. Open research topics remain: 1) optimization of tools to ensure prompt and accurate IFD diagnosis to avoid unnecessary exposure to antifungals, drug interactions and cost; 2) refinement of treatment for resistant/refractory strains.","PeriodicalId":12184,"journal":{"name":"Expert Opinion on Pharmacotherapy","volume":" ","pages":"1453-1482"},"PeriodicalIF":2.5,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141878615","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

New pharmaceutical-based strategies that foster the development and promulgation of globally effective medical countermeasures for radiation exposure injuries. 以药物为基础的新战略，促进开发和推广全球有效的辐照伤害医疗对策。

IF 2.5 3区医学

Expert Opinion on Pharmacotherapy Pub Date : 2024-08-01 Epub Date: 2024-08-19 DOI: 10.1080/14656566.2024.2394165

Vijay K Singh, Thomas M Seed

引用次数: 0

Evaluation of infectious morbidity due to BTK inhibitors in indolent B-cell lymphomas: latest research findings and systematic analysis. 评估BTK抑制剂在不显性B细胞淋巴瘤中的感染性发病率：最新研究成果和系统分析。

IF 2.5 3区医学

Expert Opinion on Pharmacotherapy Pub Date : 2024-08-01 Epub Date: 2024-08-13 DOI: 10.1080/14656566.2024.2390121

Constantin A Dasanu, Samar K Mann, Melvin Baidya, Xolani P Mdluli, Ann E Stapleton, Ion Codreanu

{"title":"Evaluation of infectious morbidity due to BTK inhibitors in indolent B-cell lymphomas: latest research findings and systematic analysis.","authors":"Constantin A Dasanu, Samar K Mann, Melvin Baidya, Xolani P Mdluli, Ann E Stapleton, Ion Codreanu","doi":"10.1080/14656566.2024.2390121","DOIUrl":"10.1080/14656566.2024.2390121","url":null,"abstract":"Introduction: Randomized clinical trials (RCTs) have suggested that BTK inhibitors (BTKis) might increase infectious disease (ID) risk. Systematic analysis of this topic as derived from RCTs and clinical practice is needed.Areas covered: An extensive Medline, Embase, and Cochrane search of peer-reviewed sources reporting on ID morbidity in patients on BTKis was performed (1 January 2014 - 31 December 2013). Contribution of intrinsic immune defects in indolent B-cell lymphomas to this morbidity was carefully considered.Expert opinion: Patients with indolent B-cell lymphomas display a wide range of innate and adaptive immune defects. In addition, BTKi use is linked with an increased signal of upper respiratory tract infections (URTIs) and pneumonias, mainly grade 1-2. These agents also increase the risk of rare invasive fungal infections (IFIs), mainly due to Cryptococcus and Aspergillus spp. with a peak within several months after the start of therapy. More than half of these IFIs are fatal. Research suggests a similar ID risk across 1st, 2nd and 3rd generations of BTKis, all causing B-cell dysfunction due to BTK inhibition, along with off-target functional neutrophil/macrophage alterations. Expanding the knowledge base on ID morbidity in patients on BTKis would facilitate timely diagnosis and treatment, and improve clinical outcomes.","PeriodicalId":12184,"journal":{"name":"Expert Opinion on Pharmacotherapy","volume":" ","pages":"1525-1540"},"PeriodicalIF":2.5,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141897177","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Exploring odevixibat's efficacy in alagille syndrome: insights from recent clinical trials and IBAT inhibitor experiences. 探索奥德韦希巴特对阿拉吉利综合征的疗效：从近期临床试验和 IBAT 抑制剂经验中获得的启示。

IF 2.5 3区医学

Expert Opinion on Pharmacotherapy Pub Date : 2024-08-01 Epub Date: 2024-08-21 DOI: 10.1080/14656566.2024.2392873

Chaowapong Jarasvaraparn, Minna Rodrigo, Christopher Hartley, Wikrom Karnsakul

{"title":"Exploring odevixibat's efficacy in alagille syndrome: insights from recent clinical trials and IBAT inhibitor experiences.","authors":"Chaowapong Jarasvaraparn, Minna Rodrigo, Christopher Hartley, Wikrom Karnsakul","doi":"10.1080/14656566.2024.2392873","DOIUrl":"10.1080/14656566.2024.2392873","url":null,"abstract":"Introduction: Alagille syndrome (ALGS) is a rare, genetic, multisystem disorder commonly associated with cholestatic liver disease; patients with ALGS may experience elevated serum bile acids and severe pruritus with associated impaired sleep. The ileal bile acid transporter (IBAT) is located on the luminal surface of enterocytes in the terminal ileum; this transport protein mediates resorption of conjugated bile acids for recirculation back to the liver. Inhibition of IBAT disrupts the enterohepatic circulation and leads to fecal elimination of bile acids.Areas covered: Here, the role of odevixibat as a novel, nonsurgical approach to interrupting the enterohepatic circulation from the intestine by inhibition of IBAT is reviewed, specifically in reference to currently available data on pharmacologic IBAT inhibition. IBAT inhibition has been shown to reduce serum bile acids and pruritus in trials of cholestatic liver diseases in children including ALGS.Expert opinion: Odevixibat or IBAT inhibitor should be considered as a first-line treatment for ALGS to improve pruritis, quality of life and liver-related outcomes including absence of liver transplant, surgical biliary diversion, hepatic decompensation, and death.","PeriodicalId":12184,"journal":{"name":"Expert Opinion on Pharmacotherapy","volume":" ","pages":"1647-1655"},"PeriodicalIF":2.5,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141999664","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Reshaping respiratory care: potential advances in inhaled pharmacotherapy in asthma. 重塑呼吸系统护理：哮喘吸入药物疗法的潜在进展。

IF 2.5 3区医学

Expert Opinion on Pharmacotherapy Pub Date : 2024-08-01 Epub Date: 2024-08-08 DOI: 10.1080/14656566.2024.2389258

Boudewijn J H Dierick, Amber A Eikholt, Susanne J van de Hei, Jean W M Muris, Huib A M Kerstjens, Job F M van Boven

{"title":"Reshaping respiratory care: potential advances in inhaled pharmacotherapy in asthma.","authors":"Boudewijn J H Dierick, Amber A Eikholt, Susanne J van de Hei, Jean W M Muris, Huib A M Kerstjens, Job F M van Boven","doi":"10.1080/14656566.2024.2389258","DOIUrl":"10.1080/14656566.2024.2389258","url":null,"abstract":"Introduction: Asthma is a common disease with a global burden of 358 million patients. Despite improvements in pharmacological and non-pharmacological treatments, many patients still do not achieve complete asthma control. Therefore, innovative pharmacotherapy is important.Areas covered: Following a semi-structured search in Pubmed, an overview of advances in inhaled asthma therapy is provided, looking at innovations in digital inhalers, eco-friendly inhalers and novel inhaled biologic therapies, antibiotics and vaccines, as well as other potential novel asthma therapy targets.Expert opinion: Digital inhalers, sending reminders and monitoring inhalation technique electronically, can support medication adherence and improve asthma control. To reduce the global warming potential of traditional aerosols used in pressurized metered-dose inhalers (HFA-134a, HFA-227ea), greener alternatives are under development (HFA-152a, HFO-1234ze) that are expected to be available by 2025. Current pharmacological advances in asthma therapy are mainly achieved by novel biologicals (anti-IgE, anti-IL5, anti-IL4/13, and anti-TSLP) targeting specific severe asthma phenotypes. While injection is the usual administration route for biologics and vaccines used in asthma, inhalation is an option being explored, although several (mainly formulation) challenges need to be overcome. Other potential novel future inhaled asthma therapies include anti-IL-33/ST2 biologicals and JAK inhibitors, all still requiring more clinical evidence.","PeriodicalId":12184,"journal":{"name":"Expert Opinion on Pharmacotherapy","volume":" ","pages":"1507-1516"},"PeriodicalIF":2.5,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141888892","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pharmacotherapy for focal epilepsy: how close are we to a cure? 局灶性癫痫的药物治疗：我们离治愈还有多远？

IF 2.5 3区医学

Expert Opinion on Pharmacotherapy Pub Date : 2024-08-01 Epub Date: 2024-08-14 DOI: 10.1080/14656566.2024.2392879

Arne Reimers

引用次数: 0

Cardio-reno-vascular protection in type 2 diabetes mellitus: new insights into pharmacotherapeutic management. 2 型糖尿病的心肾血管保护：药物治疗管理的新见解。

IF 2.5 3区医学

Expert Opinion on Pharmacotherapy Pub Date : 2024-08-01 Epub Date: 2024-08-19 DOI: 10.1080/14656566.2024.2392017

Oliwia Janota, Hanna Kwiendacz, Anna Olejarz, Aleksandra Włosowicz, Patrycja Pabis, Janusz Gumprecht, Uazman Alam, Gregory Y H Lip, Katarzyna Nabrdalik

{"title":"Cardio-reno-vascular protection in type 2 diabetes mellitus: new insights into pharmacotherapeutic management.","authors":"Oliwia Janota, Hanna Kwiendacz, Anna Olejarz, Aleksandra Włosowicz, Patrycja Pabis, Janusz Gumprecht, Uazman Alam, Gregory Y H Lip, Katarzyna Nabrdalik","doi":"10.1080/14656566.2024.2392017","DOIUrl":"10.1080/14656566.2024.2392017","url":null,"abstract":"Introduction: From 2008 and following the withdrawal of rosiglitazone, obligatory cardiovascular outcomes trials are performed for glucose lowering drugs introduced to the market to ensure their cardiovascular (CV) safety. Paradoxically, these studies have demonstrated CV safety but also shown additional cardio-reno-vascular protection of some therapeutic agents. Additionally, nonsteroidal mineralocorticoid receptor antagonists (ns-MRA) have emerged as novel drugs for cardio - and renoprotection in type 2 diabetes (T2D) and chronic kidney disease (CKD). In addition to atherosclerotic CV disease, heart failure (HF) and CKD are important clinical problems in T2D leading to poor quality of life and premature death as such cardio-reno-vascular protection is an important clinical issue.Areas covered: We provide new insights into pharmacotherapeutic cardio-reno-vascular protection in T2D based on the new glucose lowering drugs and ns-MRA. PUB MED/CINAHL/Web of Science/Scopus were searched (May 2024).Expert opinion: The conventional glucose lowering approach alone which was implemented for decades is now replaced by the use of disease modifying drugs which lower the rates of CV events, HF decompensation, hospitalization due to HF, slow progression of CKD and all-cause mortality. Indeed, the choice of medications in T2D should be focused on underlying co-morbidities with cardio-reno-vascular protection rather than a gluco-centric approach.","PeriodicalId":12184,"journal":{"name":"Expert Opinion on Pharmacotherapy","volume":" ","pages":"1605-1624"},"PeriodicalIF":2.5,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141987748","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

What are the future prospects for polycythemia vera pharmacotherapies for patients with hydroxyurea resistance? 针对羟基脲耐药患者的多发性红细胞症药物治疗的未来前景如何？

IF 2.5 3区医学

Expert Opinion on Pharmacotherapy Pub Date : 2024-08-01 Epub Date: 2024-08-26 DOI: 10.1080/14656566.2024.2396029

Megan Metzger, John Mascarenhas

引用次数: 0

New and developing first line pharmacotherapies for treating non-Hodgkin lymphoma. 治疗非霍奇金淋巴瘤的新型一线药物疗法。

IF 2.5 3区医学

Expert Opinion on Pharmacotherapy Pub Date : 2024-08-01 Epub Date: 2024-08-21 DOI: 10.1080/14656566.2024.2393759

Bruce Hough, Olga Lytvynova, Ariel Sindel, Patrick Willard, Victor Yazbeck

{"title":"New and developing first line pharmacotherapies for treating non-Hodgkin lymphoma.","authors":"Bruce Hough, Olga Lytvynova, Ariel Sindel, Patrick Willard, Victor Yazbeck","doi":"10.1080/14656566.2024.2393759","DOIUrl":"10.1080/14656566.2024.2393759","url":null,"abstract":"Introduction: Non-Hodgkin lymphomas (NHLs) encompass a wide range of diseases from precancerous states such as monoclonal B-cell lymphocytosis to the rapidly growing Burkitt lymphoma. In 2022, we witnessed two new classifications for these malignant lymphoid tumors: The World Health Organization (WHO) 5th edition Classification of Haematolymphoid Tumours and the International Consensus Classification of Mature Lymphoid Neoplasms (ICC).Areas covered: Given our improved understanding of the mechanisms underlying lymphomagenesis at the molecular level, several novel agents have been or are being actively developed, including targeted therapies and immunotherapies. Therefore, this review features new and developing first-line pharmacotherapies in NHL. It is organized by the mechanism of action of the drug with the relevant key trials highlighted.Expert opinion: We provide an overview of the development of curative combination chemotherapies for lymphomas, and then discuss the importance of working on a unified classification for these tumors. We discuss resistance to targeted therapies, particularly with the continuous use of Bruton tyrosine kinase inhibitors, how to sequence T-cell therapies (bispecific T-cell engagers and chimeric antigen receptor therapy), and the impact of financial toxicity. We also review possible strategies to increase cure rates at lower costs, with less toxicity, and while promoting global health.","PeriodicalId":12184,"journal":{"name":"Expert Opinion on Pharmacotherapy","volume":" ","pages":"1677-1689"},"PeriodicalIF":2.5,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141995617","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The pharmacology of antiplatelet agents for primary, secondary, and tertiary prevention of ischemic stroke. 用于缺血性中风一级、二级和三级预防的抗血小板药物的药理学。

IF 2.5 3区医学

Expert Opinion on Pharmacotherapy Pub Date : 2024-07-01 Epub Date: 2024-08-02 DOI: 10.1080/14656566.2024.2385135

Claudio Laudani, Davide Capodanno, Dominick J Angiolillo

{"title":"The pharmacology of antiplatelet agents for primary, secondary, and tertiary prevention of ischemic stroke.","authors":"Claudio Laudani, Davide Capodanno, Dominick J Angiolillo","doi":"10.1080/14656566.2024.2385135","DOIUrl":"10.1080/14656566.2024.2385135","url":null,"abstract":"Introduction: Ischemic etiology accounts for two thirds of all strokes in which platelet activation and aggregation play a major role. A variety of antiplatelet therapies have been tested for primary, secondary, and tertiary prevention, with certain patient subtypes benefiting more than others from a specific regimen.Areas covered: This review aims at synthetizing current evidence on pharmacology of antiplatelet agents approved for primary, secondary, and tertiary stroke prevention and their application among possible patient subtypes that may benefit more from their administration.Expert opinion: Management of ischemic stroke has largely evolved over the past decades. A better understanding of stroke pathophysiology has allowed to identify patients who can benefit most from antiplatelet therapies, with varying degrees of benefit depending on whether these agents are being used for primary, secondary, or tertiary prevention. Importantly, the antiplatelet treatment regimens currently available have expanded and no longer limited to aspirin but include other drugs such as P2Y12 and phosphodiesterase inhibitors, also used in combination, as well as precision medicine approaches using genetic testing aiming at optimizing the safety and efficacy in this population.","PeriodicalId":12184,"journal":{"name":"Expert Opinion on Pharmacotherapy","volume":" ","pages":"1373-1390"},"PeriodicalIF":2.5,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141751478","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0